Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2-Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan.
作者信息
Amano Masayuki, Maeda Kenji, Tsuchiya Kiyoto, Shimada Shinya, Mitsuya Hiroaki
机构信息
Department of Hematology, Rheumatology, and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
出版信息
J Infect Dis. 2022 Nov 28;226(11):2038-2039. doi: 10.1093/infdis/jiac209.
Abstract
摘要
相似文献
1
Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2-Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan.在日本，对第二剂反应不佳的疫苗接种者中，第三剂BNT162b2疫苗接种引发了显著高水平的新冠病毒中和抗体。
J Infect Dis. 2022 Nov 28;226(11):2038-2039. doi: 10.1093/infdis/jiac209.
2
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.接种疫苗人群中 SARS-CoV-2 病毒中和抗体滴度与刺突抗体和 ACE2 抑制的相关性。
Microbiol Spectr. 2022 Oct 26;10(5):e0131522. doi: 10.1128/spectrum.01315-22. Epub 2022 Sep 19.
3
Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination.
J Infect. 2022 Nov;85(5):573-607. doi: 10.1016/j.jinf.2022.07.024. Epub 2022 Jul 31.
4
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
5
Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.在血液透析患者中，第三次接种 BNT162b2 疫苗前后对 B.1.617.2（德尔塔）变异株的中和抗体活性。
Front Immunol. 2022 Mar 4;13:840136. doi: 10.3389/fimmu.2022.840136. eCollection 2022.
6
Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.针对第三剂 BNT162b2 COVID-19 疫苗的细胞和体液免疫反应 - 一项前瞻性观察研究。
Front Immunol. 2022 Jul 1;13:896151. doi: 10.3389/fimmu.2022.896151. eCollection 2022.
7
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.接种 BNT162b2 疫苗后医护人员抗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白抗体效价和中和活性的相关因素。
PLoS One. 2022 Jun 10;17(6):e0269917. doi: 10.1371/journal.pone.0269917. eCollection 2022.
8
Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).异源ChAdOx1-S/BNT162b2疫苗接种：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中和抗体反应
Clin Infect Dis. 2022 Apr 9;74(7):1315-1316. doi: 10.1093/cid/ciab705.
9
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
10
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
引用本文的文献
1
A high-throughput, fully automated competition assay to evaluate SARS-CoV-2 neutralizing responses and epitope specificity in clinical samples.一种用于评估临床样本中SARS-CoV-2中和反应和表位特异性的高通量、全自动竞争检测方法。
Sci Rep. 2025 Apr 4;15(1):11589. doi: 10.1038/s41598-025-94317-2.
2
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.二价 BNT162b2 疫苗接种的医护人员（有或无风险因素）或感染奥密克戎后，对奥密克戎亚谱系（BA.2/BA.5/BQ.1.1/XBB/XBB.1.5）的中和作用。
Sci Rep. 2023 Oct 13;13(1):17404. doi: 10.1038/s41598-023-44484-x.
3
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.KD-414 新冠灭活疫苗在成年人中的单剂加强免疫的免疫原性和安全性：日本一项开放标签、单中心、非随机、对照研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2193074. doi: 10.1080/21645515.2023.2193074. Epub 2023 Apr 13.
4
Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.接种异源/同源新冠疫苗的医护人员血清对奥密克戎BA.2/BA.5中和活性的比较
J Infect. 2023 May;86(5):e130-e132. doi: 10.1016/j.jinf.2023.01.038. Epub 2023 Feb 2.
5
Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants.COVID-19 恢复期血浆中 IgG 抗体对 SARS-CoV-2 变异株的中和活性。
Sci Rep. 2023 Jan 23;13(1):1263. doi: 10.1038/s41598-023-28591-3.
本文引用的文献
1
Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2在单一源头社区暴发中的快速传播
Clin Infect Dis. 2022 Aug 24;75(1):e44-e49. doi: 10.1093/cid/ciac203.
2
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults.老年人mRNA加强免疫后奥密克戎中和血清活性的持久性。
Lancet Infect Dis. 2022 Apr;22(4):445-446. doi: 10.1016/S1473-3099(22)00135-9. Epub 2022 Feb 28.
3
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.mRNA 加强免疫可引发针对 SARS-CoV-2 奥密克戎变异株的强效中和血清活性。
Nat Med. 2022 Mar;28(3):477-480. doi: 10.1038/s41591-021-01676-0. Epub 2022 Jan 19.
4
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.基于信使核糖核酸的新冠病毒疫苗加强针可诱导针对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和免疫力。
Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6.
5
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.BNT162b2 疫苗接种者中和/SARS-CoV-2-S1 结合抗体反应与不良反应和免疫动力学的相关性。
Sci Rep. 2021 Nov 24;11(1):22848. doi: 10.1038/s41598-021-01930-y.
6
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine.第三剂 BNT162b2 mRNA 疫苗的有效性。
J Infect Dis. 2022 Jan 5;225(1):30-33. doi: 10.1093/infdis/jiab556.
Zotero 插件